Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V4MB
|
|||
| Former ID |
DCL000619
|
|||
| Drug Name |
Remogliflozin etabonate
|
|||
| Synonyms |
GSK-189075; GSK-189075A; KGT-1681
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-1/2 diabetes [ICD-11: 5A10-5A11] | Phase 2 | [1] | |
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [2] | ||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H38N2O9
|
|||
| Canonical SMILES |
CCOC(=O)OCC1C(C(C(C(O1)OC2=NN(C(=C2CC3=CC=C(C=C3)OC(C)C)C)C(C)C)O)O)O
|
|||
| InChI |
1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
|
|||
| InChIKey |
UAOCLDQAQNNEAX-ABMICEGHSA-N
|
|||
| CAS Number |
CAS 442201-24-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/glucose cotransporter 2 (SGLT2) | Target Info | Inhibitor | [2] |
| Sodium/glucose cotransporter 2 (SLC5A4) | Target Info | Blocker | [3] | |
| Reactome | Hexose transport | |||
| Na+-dependent glucose transporters | ||||
| Inositol transporters | ||||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021813) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.